Compared to Estimates, TransMedics (TMDX) Q1 Earnings: A Look at Key Metrics

Financial Performance - For the quarter ended March 2025, TransMedics reported revenue of $143.54 million, reflecting a 48.2% increase year-over-year [1] - The earnings per share (EPS) was $0.70, up from $0.35 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $123.56 million by 16.17% [1] - The company delivered an EPS surprise of 141.38%, with the consensus EPS estimate being $0.29 [1] Key Metrics - TransMedics' shares returned 27.1% over the past month, outperforming the Zacks S&P 500 composite's 11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Geographic Revenue Breakdown - Revenue from the United States was $138.62 million, surpassing the average estimate of $119.11 million, representing a year-over-year increase of 50.9% [4] - Revenue from all other countries was $4.07 million, slightly below the average estimate of $4.21 million, showing a year-over-year decline of 0.6% [4] OCS Product Revenue - OCS Lung net revenue was $4.01 million, below the average estimate of $5.19 million, reflecting a year-over-year decrease of 29.2% [4] - OCS Liver net revenue reached $108.86 million, exceeding the average estimate of $87.87 million, marking a 62.7% increase year-over-year [4] - OCS Heart net revenue was $29.82 million, slightly below the average estimate of $30.01 million, indicating a year-over-year increase of 27.8% [4]